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1. Introduction 
Significant improvements have been made during the last 20 years in the therapy of renal 
diseases including the broadening of treatment options. Gene therapy is a potential 
modality for renal diseases for which we are yet unable to offer specific treatment. In spite of 
the revolutionary progress in the field of gene therapy, delivery to achieve safe clinical 
application remains one of the biggest challenges in biomedical research. In the present 
chapter we focus on nucleic acid (NA) therapy targeting messenger (mRNA) and micro 
(miRNA) RNA in the kidney. 
2. RNA interference 
RNA interference (RNAi), the sequence-specific post-transcriptional gene silencing 
mediated by small (19-25 nucleotide length) double-stranded RNAs (dsRNA), is of potential 
use as a therapeutic approach for the treatment of a variety of diseases (Dykxhoorn & 
Lieberman, 2006; Castanotto & Rossi, 2009). Small, non-coding RNA molecules such as 
microRNA (miRNA) and short interfering RNA (siRNA) are important regulators of gene 
expression, helping to control cellular metabolism, growth and differentiation, to maintain 
genome integrity, and to combat viruses and mobile genetic elements (C. Zhang, 2009; 
Moazed, 2009). 
2.1 Biogenesis of small RNAs and mechanism of action 
Following completion of the human genome project, a series of non-coding small RNAs 
have been discovered. Two main categories of small RNAs have been defined on the basis of 
their precursors. The cleavage of exogenous double-stranded RNA (dsRNA) precursors 
produced during viral infection or after artificial transfection generates siRNAs, whereas the 
processing of genome-encoded endogenous stem–loop RNA structures generates miRNAs. 
Exogenous siRNAs and endogenous miRNAs are generated from dsRNA precursors that 
are produced in or introduced into cells (Siomi H. & Siomi M.C., 2009; Bartel, 2004).  
During the mechanism of RNAi, double-stranded RNA is cleaved by an RNAseIII 
ribonuclease called Dicer into smaller fragments (21 to 23 nucleotides). The resulting 
fragments are then bound to an Argonaut family protein which functions as the core 
component of a protein–RNA complex called the RNA-induced silencing complex (RISC) or 
its nuclear form the RNA-induced transcriptional silencing complex (RITS). SiRNA/miRNA 
duplex is unwind by helicase, and the guide or antisense strand will then engage in selective 
degradation of the mRNA that is complementary to the guide strand.  
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As a post-transcriptional gene-silencing (PTGS) mechanism exogenous siRNA mediated 
RNAi causes degradation of the target mRNA and prevents protein synthesis (Rácz & 
Hamar, 2008). Physiologic function of RNAi is elimination of viral infections, as double 
stranded RNAs are often produced during the life cycle of viruses and are eliminated this 
way. However, siRNA mediated PTGS can be utilized therapeutically, by transfecting cells 
in vivo with siRNA complementary to a segment of a protein coding mRNA (Rácz & 
Hamar, 2006). The revolutionary aspect of siRNA therapy is that it acts on disease-
associated key proteins by down regulating components of the pathway without permanent 
effects on the genome. Thus, siRNA treatment has the potential to prevent injury from 
occurring in addition to addressing existing injury. 
Endogenous non-coding miRNAs are involved in post-transcriptional regulation of gene-
expression. MiRNAs are generated from endogenous hairpin structured transcripts 
throughout the genome. MiRNA encoding genes are transcribed by RNA polymerase II (pol 
II) providing long precursor transcripts, known as primary miRNAs (pri-miRNAs). After 
transcription, Drosha RNase: a type III nuclear ribonuclease cleaves nucleotides from the 
pri-miRNA, processing it into shorter pre-miRNAs. Nuclear export factor Exportin-5 
(Exp5/Xpo5) transports the pre-miRNA to the cytoplasm. Further cytoplasmic processing 
by Dicer (type III ribonuclease) cleaves pre-miRNA generating mature, double-stranded, 18-
25 nucleotide-long miRNA. The guide strand is incorporated into RISC and remains stably 
associated with RISC, becoming the mature miRNA. The opposite (passenger) strand is 
disposed. The miRNA guides the RISC to the target mRNA with complementary sequence. 
In case of incompletely complementary sequences, translation of the target mRNA is 
silenced, and the mRNA is degraded by the RISC in case of fully complementary sequence. 
Unlike RNAi induced by siRNA, miRNA during regulation, cleavage of the mRNA occurs 
more seldom, only by complete match between the miRNA and the mRNA (Kaucsár et al., 
2010). 
MiRNAs and siRNAs control post-transcriptional gene expression by directing 
endonuclease cleavage of the target mRNA. This mechanism of action is referred to as slicer 
activity. For slicer activity fully complementary miRNA and target mRNA sequences are 
required. However, in some cases, few mismatches can be tolerated for cleavage. MiRNAs 
may also act a slicer-independent manner such as mRNA repression, or mRNA decapping 
(Valencia-Sanchez et al., 2006).  
Regulatory miRNAs compose networks. This notion is supported by (i) the high number of 
non-coding RNAs which are functionally active and target signaling molecules, (ii) many 
genes encoding miRNAs are closely clustered in the genome and (iii) in some cases different 
miRNAs control a single mRNA target or vice versa a single miRNA may influence 
expression of multiple different target proteins. Human and murine kidney specific miRNA 
expression profiles have been reported and summarized (in Kaucsár et al., 2010). 
2.1 Further small RNA types 
A non-coding RNA (ncRNA) is a functional RNA molecule that is not translated into a 
protein. Non-coding RNAs include long known transfer RNA (tRNA) and ribosomal RNA 
(rRNA) involved in translation, as well as newly described RNAs involved in gene 
expression regulation such as:  
 Small nuclear RNA (snRNA) - involved in mRNA splicing.  
 Small nucleolar RNA (snoRNA) - direct the modification of ribosomal RNAs.  
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 Micro RNA (miRNA) and short interfering RNA (siRNA) - regulate gene expression.  
 The P-element induced wimpy testis in Drosophila (piwi) (Saito et al., 2006) proteins 
regulate stem- and germ-line cell division (Cox et al., 2000). Piwi-interacting RNAs 
(piRNAs) isolated from mouse testes (Kim, 2006) are involved in defense of germ-line 
cells against parasitic DNA elements such as retrotransposons.  
MiRNAs and siRNAs are about 20-25 nucleotides long. piRNAs have a broader average size 
~24–31 nucleotides. siRNAs have been widely used in functional genomics and also have 
therapeutic potential.  
3. Challenges in RNA-based therapy knocking down disease 
Presently, therapeutic RNAi application faces three major obstacles:  
i. stability of siRNA when administered in vivo,  
ii. delivery across barriers in living organisms, and  
iii. circumvention of immune response.  
Efforts to improve the effect of RNAi-based nucleic acid (NA) therapy include,  
i. stabilization of the nucleic acid against enzymatic degradation,  
ii. enhancing cellular uptake of the nucleic acid, and  
iii. limiting immunoactivation during in vivo application. 
Stability of siRNA in vivo in biological milieu is one of the obstacles for therapeutic 
application. Numerous modifications are available, since chemically synthesized siRNAs 
became cheap and easy to synthesize. (For chemical modifications see 4.2.). 
Delivery problems include rapid degradation of NAs and rapid renal clearance. Double 
stranded NAs have an advantageous resistant profile against nuclease degradation which 
can be further reduced by chemical modifications. Rapid renal clearance eliminates the 
therapeutically applied small NA from the circulation; however, this can be utilized as an 
advantage in targeting the kidney as tubular epithelial cells (TEC) may take up the NAs 
from the ultrafiltrate. Thus, TEC can be efficiently targeted this way (Molitoris et al., 2009). 
Exogenously administered siRNAs may have undesired side effects (Rácz & Hamar, 2008).  
Such unwanted side-effects may include: unintended knockdown of partially 
complementary sequences may occur resulting in off-target silencing. Side effects induced 
by siRNAs have been shown to be concentration dependent. Off-target silencing is more 
likely to occur in case of high siRNA concentrations but sometimes may occur even in low 
siRNA concentration (Jackson et al, 2003). Moreover, high siRNA concentration can also 
induce gene activation of apoptosis and stress response (Semizarov et al., 2003) or can lead 
to non-selective translational shutdown (erre nem találtam hiv-t).  
Immunological response is an other obstacle in therapeutic siRNA application. Toll-like 
receptors (TLRs) recognize pathogen-associated molecular patterns (PAMPs), such as 
bacterial wall endotoxins (LPS), viral dsRNA, and cytosine-guanine (CG) motifs. TLRs also 
recognize siRNA, and consequently TLR intracellular signaling pathways are activated 
leading to immune activation. Moreover, dsRNAs induce interferon response directly. 
Delivery across barriers in living organisms, e.g. across biological membranes is a major 
issue for potential therapeutic application of siRNAs. Chemical modifications, 
complexation, conjugation with lipid bilayer-penetrating carriers assist this purpose. This 
chapter focuses on delivery issues of RNAi in order to influence pathological conditions in 
the kidney. 
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4. Delivery strategies 
Delivery strategies to induce cellular uptake of the therapeutic nucleic acid include physical 
force or vector systems such as viral-, lipid- or complex- based delivery, or nanocarriers. 
From the initial applications with less possible clinical relevance, when NAs were addressed 
to renal cells with hydrodynamic high pressure injection systemically, a wide range of gene 
therapeutic viral and non-viral carriers have been applied already to target 
posttranscriptional events in different animal kidney disease models in vivo. 
4.1 Physical approaches 
One of the strategies for introducing NAs into cells and tissues is physical force. During 
these approaches hydrodynamic pressure is applied to force the NAs into tissue 
parenchyma and cells. The hydrodynamic pressure can be established systemically during 
the hydrodynamic procedure or locally during direct injections into the target organ. 
Intrarenal, local delivery to the kidney can be achieved by different routes such as via the 
renal artery targeting glomeruli, via the renal vein targeting the tubulointerstitium, via the 
ureter into the renal pelvis and by subcapsular administration for intraparenchymal effects. 
Effects of the hydrodynamic pressure can be further enhanced by temporary pore openings 
in cell membranes by electroporation or sonoporation with ultrasound or micro-injection.  
DY547-labeled non-target control siRNA or rhodamine-labeled p85ǂ siRNA uptake 
followed by hydrodynamic or standard tail vein injection was noted in the kidney with 
consequent protein inhibition in case of p85ǂ siRNA, but no signal was observed after 
intraperitonal or per rectum administration (Larson et al., 2007). Hydrodynamic 
administration resulted in a higher uptake in the kidney as well as in other target organs in 
contrast to standard intravenous injection (Larson et al., 2007). 
In a mouse model of renal ischemia-reperfusion, Fas siRNA pretreatment hydrodynamically 
through the tail vein and/or injected locally into renal vein protected NMRI mice from  
renal ischemia-reperfusion injury (Hamar et al., 2004). Sufficient downregulation of the  
FAS apoptosis receptor substantially reduced functional deterioration of the kidney 
manifesting in significant survival advantage. Similar good results were achieved by 
silencing apoptosis cascade elements (Zheng et al., 2008) or the central inflammatory 
signaling element: nuclear factor kappa-b (NFkB) (Feng et al., 2009).  
Apoptosis antagonizing transcription factor (AATF), a regulator of apoptotic pathways, was 
targeted in an in vitro model of kidney ischemia-reperfusion injury. In human kidney 
proximal tubule HK-2 cells and in primary renal tubule epithelial cells RNA interference–
mediated silencing of AATF heightened whereas overexpression of transgenic AATF 
ameliorated superoxide accumulation and apoptotic cell death following hypoxia (Xie & 
Guo, 2006). 
Gremlin siRNA plasmid suspended in 2 ml of the TransIT-EE Hydrodynamic buffer 
delivered weekly by hydrodynamic tail vein injection reversed diabetic nephropathy in 
streptozotocin-induced diabetic, uninephrectomized mice. Furthermore, high glucose 
induced collagen IV and MMP-2 activity was inhibited by lipofectamin transfection of the 
same gremlin construct in cultured mouse mesangial cells (Q. Zhang et al., 2010). Gremlin is 
highly expressed in kidney with diabetic nephropathy, mainly observed in areas of 
tubulointerstitial fibrosis, and its mRNA level correlates with the degree of the fibrosis.  
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4.2 Chemical modifications 
Spontaneous uptake of siRNA by cells without additional carrier is reportedly less efficient 
when compared to strategies employing transfection reagents that complex or encapsulate 
siRNA. Chemical modification and bioconjugation with vehicles can drastically improve the 
stability and cellular uptake, allowing improvements in selectivity and reduced toxicity.  
While phosphodiester oligonucleotides are unstable in the biological milieu, several 
chemical modifications have been applied to enhance stability.  
Before RNAi was discovered antisense oligonucleotides were used for experimental nucleic 
acid sequence specific inhibition of protein synthesis. Main differences between siRNA used 
in RNAi and previously popular antisense oligonucleotides (ASOs) is, that ASOs are single 
stranded and thus, much more sensitive to extracellular nuclease degradation, whereas 
siRNAs are more resistant due to their double stranded structure (Paroo & Corey, 2004). 
First generation of chemically modified oligonucleotides was phosphorothioate RNA, later 
2’ sugar modifications (2’-O-methyl and 2’-O-methoxy-ethyl-RNAs) were introduced 
(Monia, 1997). The hydrophilic character and anionic backbone of siRNAs reduces their 
uptake by the cells. While siRNA duplexes are relatively more stable in serum than single 
stranded siRNA, they easily undergo degradation by nucleases in vivo. This, with their 
limited capability to cross cellular lipid bilayers, represents a significant barrier to the 
therapeutic development of siRNA. A variety of chemical modifications have been tested to 
enhance effectiveness of oligonucleotide intracellular delivery, including chemical 
modifications to sugars (2’-sugar), backbones, or nucleobases. Conjugation to membrane 
penetrating vehicles has been also demonstrated to enhance stability, prevent triggering of 
an immune response, control pharmacokinetic profiles and reduce nonspecific effects. 
However, some of these modifications may affect biological activity (Rácz & Hamar, 2006, 
2008). 
4.3 Viral vectors 
Besides chemical modifications vector systems have been used widely to protect and deliver 
NAs in vitro and in vivo. Gold standards of gene delivery are viral vectors. Several kinds of 
viral vectors have been used already in delivery applications into the kidney. Strategies 
employed in previous gene therapy applications can be readily adapted for use in RNAi. 
Viral vector containing expression cassettes coding for shRNA precursors, as an alternative 
to siRNA administration have been successfully used in the kidney employing plasmid 
DNA (pDNA) vectors. Few studies describe renal shRNA delivery with viral vectors such 
as, replication-deficient adenoviral delivery in rat cortical tubules, glomeruli or tubular 
epithelium of the outer medulla or lentiviral retrograde ureteral infusion to tubular epithelial 
cells in mice. Intraparenchymal delivery of lentivirus particularly induced transgene 
expression in the cortical and corticomedullary area of the kidney with lower expression in 
the medullary part. In a rat renal transplantation model, perfusion of the donor kidney with 
lentiviral vector induced significant target gene silencing. Transplantation offers an ex-vivo 
window enabling significant reduction of possible systemic side-effects of NA therapy. 
From a safety perspective, the use of lentiviral vectors may lead to unwanted insertion of the 
construct in vital gene regions. 
Recombinant adenoviruses and adeno-associated viruses (AVs, AAVs) are capable of transducing 
cells with high efficiency. However, adenoviral vectors have been reported to be 
immunogenic. In mice, intraparenchymal or intrapelvic delivery of recombinant AAV 
induced transgene expression by epithelium of the tubules or mainly in the medulla, 
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respectively. Despite recent concerns, recombinant AAVs are attractive vectors as they 
appear to be safe and capable of long-term gene expression. Although efficient delivery 
vehicles, adenoviruses are strong stimulators of innate and adaptive immune responses. 
This may cause toxicity and limit repeated administration. To modify tropism and reduce 
immune responses, recent studies have used surface modified or helper-dependent ‘gutless’ 
vectors. Helper dependent and chemically modified vectors may have an improved safety 
profile that could be better suited to clinical application. 
Adeno-associated (AAV) virus-2 vector was used for inhibiting mineralocorticoid receptor 
(MR) by MR-shRNA expressing AAV. AAV MR-shRNA reduced MR expression in the 
kidney and prevented blood pressure increase, albuminuria, and renal failure in cold-
induced hypertension in Sprague–Dawley rats (Wang et al., 2006). 
Anti-luciferase siRNA-expressing piGENE hU6-stem21 pDNA was co-injected 
hydrodynamically with pGL3 firefly luciferase-expressing pDNA via tail vein in ddY mice 
in a dose- and time-dependence study of vector-based in vivo RNAi (Kobayashi et al., 2004). 
Authors investigated silencing efficiency in liver, kidney, lung and muscle. Viral vector 
mediated RNA silencing of the transgene 1 day after intravenous injection was almost as 
efficient in the kidney as in the liver. 
Hemagglutination virus of Japan–envelope vector was used in uninephrectomized 
streptozotocin-induced diabetic mice to target mammalian translocase of inner 
mitochondrial membrane 44 (TIM44) (Y. Zhang et al., 2006).  TIM44, a membrane anchor of 
mitochondrial heat-shock protein 70 (mtHsp70) to TIM23 complex is upregulated in diabetic 
mouse kidneys and is held responsible for superoxide production. RNAi to TIM44 reduced 
proteinuria, renal hypertrophy, renal cell proliferation and apoptosis, and suppressed 
superoxide production.  
4.4 Non-viral carriers 
Applying non-viral vehicles constitute promising alternatives to the use of viral vectors. 
Delivery of siRNA, especially with cationic preparations and biodegradable components 
have much better safety profiles than their viral counterparts, though their transfection 
efficiency is generally lower. The positive charge facilitates complex formation with NAs 
and endocytosis of the complex. The complex between the cationic carrier (lipids, polymers, 
peptides, nanoparticles) and the anionic NA is formed by electrostatic interaction.  
4.4.1 Lipid-based delivery 
Various lipid-based delivery systems have been developed for in vivo application of siRNA, 
including liposomes, micelles, emulsions, and solid lipid nanoparticles. Application of 
liposome-mediated gene carriers retrospects a long path from the seventies. Complexes 
between cationic lipid and DNA are named lipoplexes. Due to the high complexity of the 
self-assembly process, little is known about the mechanisms of formation. Multicomponent 
lipoplexes, incorporating three to six lipid species, have emerged as promising delivery 
candidates, with 10 to 100 times higher efficiency than binary complexes usually applied for 
gene delivery (Caracciolo et al., 2005, 2009). Our understanding about the bio-distribution of 
RNA-liposome complex is rather scarce; however, it is known to depend on the colloidal 
properties of the complex as well as their interaction with blood components. Surface charge 
is a main issue in half-life and destination of the complex. While lipoplexes with a strong 
anionic charge are usually absorbed by scavenger cells, resulting in a rapid elimination from 
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the blood, a strongly positive surface favors the accumulation in the liver (Y.-C. Tseng et al, 
2009). 
Liposome-based transfection reagents have been successfully employed for in vivo siRNA 
delivery to the kidney, such as  
cationic lipids 
 N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP)  
 (3ǃ-[N-(N’,N’-dimethylaminoethane)-carbamoyl])-cholesterol (DC-Chol)  
or neutral helper lipids 
 1,2-dioleoyl-sn-glycero-3-phosphatid-ylcholine (DOPC),  
 dioleoylphosphatidylethanolamine (DOPE).  
Protection of nucleic acids with encapsulation into the liposome makes these lipid delivery 
strategies attractive for gene transfer. However, composition and surface charge pattern are 
important issues in organ targeting and potential immune recognition and response. 
Lipoproteins have also been tested as lipid-based transfection reagents. Efficient and 
selective siRNA conjugation to bile acids and long-chain fatty acids, or cholesterol, depends 
on interactions with lipoprotein particles, lipoprotein receptors and transmembrane proteins 
(Wolfrum et al., 2007). High-density lipoprotein (HDL) directs siRNA delivery into the liver, 
gut, kidney and steroidogenic organs, whereas low-density lipoprotein (LDL) targets siRNA 
primarily to the liver. In a delivery study of lipoprotein-siRNA complexes it has been 
ascertained that 32P-cholesterol-siRNA bound to HDL or albumin but not to LDL resulted in 
an accumulation in the kidney, while with LDL the main target organ was the liver. 
Examples of successful lipid based siRNA delivery in renal pathologies 
Intravenous RNAi-mediated inhibition of p53 delivered by lipofectamin transfection agent 
minimized renal injury in a hypoperfusion/ischemia and a cisplatin model of kidney 
damage in rats. P53 siRNA minimized renal p53 protein increase after ischemia-reperfusion 
injury. Proximal tubule cells were protected against ischemic and cisplatin-induced acute 
injury by chemically modified, 2’O-methylated p53 siRNA (Molitoris et al., 2009). Following 
i.v. injection, rapid glomerular filtration with subsequent proximal tubule brush border 
binding and endocytosis by proximal tubule cells were observed. The minimal labeling in 
the vasculature indicated rapid renal clearance. 
Renal injury and diabetic nephropathy were ameliorated by cholesterol-tagged 12/15-
lipoxygenase (12/15-LO) targeting siRNAs in streptozotocin-induced mouse model of type 
1 diabetes (Yuan et al., 2008). Lipoxygenases (LO) are a family of non-heme iron-containing 
enzymes that insert molecular oxygen into polyunsaturated fatty acids. The 12/15-LO is 
involved in mesangial cell growth and extracellular matrix protein expression during 
glomerulosclerosis. Cholesterol conjugation was applied to enhance renal siRNA uptake. 
Significant reduction of 12/15-LO mRNA level was observed in murine mesangial cells in 
vitro and the examined tissues in vivo (spleen, kidney, liver, and heart), indicating broad 
tissue biodistribution of the siRNAs. Glomerular hypertrophy and mesangial matrix 
expansion were reduced.  
Breast adenocarcinoma (MDA-MB-231) cells in vitro and in female SCID mice in vivo were 
treated with cationic liposome loaded with COX-2 siRNA (Mikhaylova et al., 2009). COX-2 
is often upregulated in cancer. DOTAP/DOPE (DD) and DOTAP/DOPE/DOPE-PEG2000 
(DDP) lipid mixtures were used for producing lipoplexes. For imaging purposes liposomes 
were loaded with different contrast agents. Incubation of DDP lipoplexes for extended 
periods demonstrated siRNA-dependent, sequence-specific downregulation of COX-2 
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protein expression in breast cancer cells. Also, tumor-bearing female SCID mice treated with 
DDP-COX-2 lipoplexes DY-647 labeled localization of COX-2 siRNA was observed in the 
tumor, lung and liver shortly after injection. In contrast, the fluorescence intensity in the 
kidney was lower, however, second highest signal of detectable fluorescence was observed 
in the kidneys 24h post injection. 
Physical approaches (such as hydrodynamic in vivo delivery) are often combined with 
adaptation of different carriers. DY547- and rhodamine-labeled, chemically modified 
siRNAs mixed with DOTAP effectively appeared in the kidney after hydrodynamic and 
standard iv. injection, while i.p. and rectal administration were unsuccessful even with 
DOTAP liposomal transfection reagent (Larson et al., 2007).  
RLIP76 multifunctional transporter, which is frequently over-expressed in malignant cells 
has been chosen as a target for kidney cancer in a study that compare anti-RLIP76 IgG, 
RLIP76 siRNA, or RLIP76 antisense oligodeoxynucleotide in Caki-2 kidney cancer xenograft 
bearing Hsd: athymic nude nu/nu mice (Singhal et al., 2009). Treatment with RLIP76 
antibody, siRNA, or antisense caused regression of established Caki-2 kidney cancer 
xenografts. Messenger RNA targeting was performed with Quiagen’s lipid-based 
TransMessenger transfection reagent. Caki-2 cells express RLIP76 3-fold compared to 
normal human kidney mesangial cells. The tumor-bearing animals were alive 4-times longer 
due to the RLIP76 antibody, RLIP76 siRNA, or RLIP76 antisense treatment. Administration 
of RLIP76 antibody, siRNA, or antisense caused regression of established Caki-2 kidney 
cancer xenografts.  
4.4.2 Polymer-based delivery 
Polymer-based delivery systems have been extensively used for plasmid DNA and more 
recently for siRNA. As with lipid-based delivery systems, polymeric delivery of siRNA 
usually involves a cationic moiety as a core component. Cationic polymers are generally 
classified into synthetic and natural polymers. Synthetic polymers include branched or 
linear poly-(etilene-imine) (PEI), poly-(L-lysine) (PLL), and cyclodextrin-based polycations. 
Natural cationic polymers include chitosan, atelocollagen, and cationic polypeptides. Cationic 
polymers (polyplexes if complexed with DNA) are key players of non-viral transfer systems 
due to their exclusive physicochemical properties (Kimura et al., 2001). Most important 
characteristics of non-viral carriers are charge ratio, which define their ability to carry NAs 
in therapeutically sufficient quantities (Almofti et al., 2003). An extensive research in 
polymer therapeutics led to new generations of polymers improving safety, 
biocompatibility, and efficiency. One novel approach aims at glomerular protein 
knockdown using poly-(ethylene-glycol)-poly-(L-lysine) (PEG-PLL) copolymer-based 
nanocarriers while avoiding size-selective restraints of the glomerular filter (Shimizu et al., 
2010). These polymer nanocarriers have enhanced delivery and retention in the kidney 
compared to naked siRNA following intraperitoneal administration, more specifically to 
cells of the glomerulus. Furthermore, the applied PLL carrier proved superior with respect 
to glomerular targeting when compared to a viral delivery of siRNA. Notably, PEI-siRNA 
complexes displayed lower renal targeting compared to naked siRNA, however, naked 
siRNA taken up in the kidney was mostly degraded, whereas renal accumulation of PEI-
siRNA resulted in a significantly higher proportion of intact siRNA (Malek et al., 2009). 
In vivo pharmacokinetics, tissue distribution and adverse effects studies of PEG-PLL 
copolymer delivered siRNAs in mice revealed that PEI complexation substantially increased 
tissue uptake compared to naked siRNA (Malek et al., 2009). Application of naked siRNAs 
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with almost no uptake of intact siRNA molecules was observed in the kidney, while PEI 
complexation led to a significant increase in levels of intact siRNAs. PEI (–PEG) complex 
uptake proved to be composition dependent. 
In an other application of PEG-PLL glomerulonephritis was ameliorated by MAPK1 siRNA 
in lupus nephritis mouse model (Shimizu et al., 2010). PEG-PLL complexed siRNA 
transfected glomeruli successfully, unlike the naked siRNA.  MAPK1 mRNA expression in 
isolated glomeruli was significantly suppressed in mice treated with the MAPK1 siRNA 
PEG-PLL complexes, whereas control or HVJ-E viral vector mediated siRNA had no effect 
on protein expression.  
Based on a conception that hyaluronic acid (HA) plays an important role on receptor-
mediated endocytosis, the effect of HA modification of siRNA/PEI complex has been 
investigated in B16F1 melanoma tumor-bearing mice (Jiang et al., 2008). The hyaluronic acid 
conjugated complex exhibited higher gene silencing efficiency in B16F1 murine melanoma 
cells with HA receptors than the siRNA/PEI complex alone. According to an in vivo 
biodistribution study, siRNA/PEI-HA complex accumulated mainly in tissues with HA 
receptors such as liver, kidney, and tumor. Anti-VEGF siRNA/PEI-HA complex was used 
successfully as target specific antiangiogenic therapeutics in the tissues with HA receptors, 
such as liver cancer and kidney cancer. Intratumoral injection of anti-VEGF siRNA/PEI-HA 
complex resulted in an effective inhibition of tumor growth by the HA receptor mediated 
endocytosis to tumor cells in mice. 
Cationized gelatin delivered plasmid DNA expressing TGF-ǃ type II receptor (TGF-ǃRII) 
complexed by siRNA prevented interstitial renal fibrosis (Kushibiki et al., 2005) in unilateral 
ureteral obstruction (UUO) model mice.  
4.4.3 Aptamers 
Aptamers (<lat.> aptus: fit), like antibodies are molecules that bind tightly to their specific 
molecular targets. Unlike antibodies aptamers can be synthesized and selected with pure 
chemical methods, and their production does not involve living systems. Target binding by 
aptamers is achieved by their 3 dimensional structure.  
RNA oligonucleotide aptamers recognize their target specifically on the basis of their unique 
3-dimensional structures. Application of aptamers as carriers is based on the specific 
interaction between the aptamer and its cellular membrane receptor. As aptamers bind their 
molecular targets like antibodies, internalization of the aptamer enables the cellular uptake 
via receptor-mediated endocytosis, thereby increasing local concentration of carried drugs 
in the targeted cells.  
Spiegelmer aptamers are l-enantiomers, which are immunologically inert, and are not 
degraded by nucleases. Ccl2 antagonistic, PEGylated spiegelmer mNOX-E36 aptamer 
ameliorated diabetic nephropathy in mice (Ninichuk et al., 2008). mNOX-E36–3’PEG 
reduced the number of glomerular macrophages, significantly improved the glomerular 
filtration rate, reduced renal Ccl2 mRNA and protein expression, and thus protected from 
diffuse glomerulosclerosis.  
Spiegelmer NOX-F37 aptamer targeting vasopressin-dependent activation of V1a and V2 
receptors effectively neutralized vasopressin (AVP) and increased diuresis in healthy rats 
(Purschke et al., 2006).  
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4.4.4 Nanoparticles 
Various types of nanoparticles are used in biomedical research. Few experiments have been 
already completed for kidney targeting.  
 Nanocrystals are crystalline structures of aggregated molecules, mostly known as 
quantum dots and are used for biological imaging, semiconductors of material research 
and chemical engineering.  
 Nanotubes are self-assembling sheets of atoms (often carbon atoms) arranged in 
tubes.  
 Fullerenes are similar to carbon nanotubes in that their molecular framework is entirely 
composed of an extensive π-conjugated carbon skeleton.  
 Dendrimers are unique molecular architectures having well defined structures with 
inner cavities to bind biomolecules that make them appropriate for gene delivery. 
Quantum dots (Qdot) were applied for bioimaging purposes in the study, where uptake of 
siRNA/PEI complexes was enhanced with hyaluronic acid (HA) conjugation (referred 
earlier in 4.4.2, Jiang et al., 2008).  
Nanofibrous scaffold mediated RNAi was applied successfully silencing GAPDH in human 
embryonic kidney 293 cells (HEK 293) (Cao et al., 2010).  Polycaprolactone (PCL) nanofiber 
encapsulated GAPDH siRNA, and the released intact siRNA from scaffold resulted in 
successful transfection of HEK293 cells. 
So far no attempt has been documented for fullerene- or dendrimer-based RNAi in the kidney, 
however several gene delivery studies of dendriplexes or fullerenes carrying DNA to other 
organs were published (Tomalia et al., 2007; Shcharbin et al., 2010; Zhong et al., 2008; 
Maeda-Mamiya et al., 2010).  
Polyamidoamine (PAMAM) dendrimers bound EGFP-C2 marker gene and delivered it to 
many organs after intravenous injection that resulted in high expression in liver, kidney, 
lung, and spleen (Zhong et al., 2008).  
Human embryonic kidney cells (HEK293), mouse embryonic cells (NIH/3T3), SV40 
transformed monkey kidney fibroblasts (COS-7) and human epithelioid cervical 
carcinoma cells (HeLa) were efficiently transfected with dendriplexes carrying pDNA 
encoding firefly luciferase, beta-galactosidase or green fluorescent protein (Shcharbin et 
al., 2010). 
To investigate a fullerene as nanocarrier, tetra(piperazino)fullerene epoxide (TPFE) 
conjugated Insulin 2 gene coding pDNA was administered to mice (Maeda-Mamiya  et al., 
2009). Plasmid insertion was more efficient when delivered with fullerene than when 
delivered with Lipofectin in kidney, liver and spleen. Application of TPFE fullerene carrier 
did not elevate blood urea nitrogen (BUN), whereas plasmid carried with Lipofectin 
increased BUN level that indicated a mild kidney toxicity. 
5. Conclusion 
Nucleic acid therapies reviewed in the present chapter are aimed at silencing messenger 
RNA. Recent advances in delivery systems may soon advance NA therapy from science 
fiction to science and medicine, thus enabling therapy of presently uncurable diseases of the 
kidney such as cancer, or fibrosis. 
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Delivery 
method 
Carrier Target RNA Disease Model Functional assays Author 
Hydrodynamic
/ Lipid 
TransIT In 
Vivo Gene 
Delivery 
System, 
DOTAP 
p85ǂ 
Acute 
renal 
injury 
Ischemia-
reperfusion 
Uptake, 
biodistribution 
Larson et 
al., 2007 
Hydrodynamic
/ Lipid 
Lipofectamine
2000 
Fas 
Acute 
renal 
injury 
Ischemia-
reperfusion 
Blood urea 
nitrogen, Fas 
Immunohisto-
chemistry, 
apoptosis, 
histological scoring 
Hamar et 
al., 2004 
Hydrodynamic n.a. 
Apoptosis 
cascade 
elements 
Acute 
renal 
injury 
Ischemia-
reperfusion 
n.a. 
Zheng et 
al., 2008 
Hydrodynamic n.a. 
Nuclear factor 
kappa-b 
(NFkB) 
Acute 
renal 
injury 
Ischemia-
reperfusion 
n.a. 
Feng et al., 
2009 
Hydrodynamic
/Viral 
Lipofectamine
2000 
Apoptosis 
antagonizing 
transcription 
factor (AATF)
Acute 
renal 
injury 
Ischemia-
reperfusion 
Apoptosis,
oxidative stress, 
caspase activation, 
membrane  
lipid  
peroxidation 
Xie & Guo, 
2006 
Hydrodynamic 
pBAsi mU6 
Neo/ 
TransIT-EE
Hydrodynam
ic Delivery 
System 
Gremlin 
Diabetic 
nephro-
pathy 
Streptozotozin
-induced 
diabetes 
Proteinuria, serum 
creatinine, 
glomerular and 
tubular 
diameter, collagen 
type IV/BMP7 
expression
Q. Zhang et 
al., 2010 
Viral/Lipid 
pSUPER 
vector/ 
Lipofectamin
e 
TGF-ǃ type II 
receptor 
Interstitial 
renal 
fibrosis 
Unilateral 
urethral 
obstruction 
ǂ-SMA expression, 
collagen content, 
Kushibiki 
et al., 2005 
Viral 
Adeno-
associated 
virus-2 
Mineral 
corticoid 
receptor 
Hyper-
tension 
caused 
renal 
damage 
Cold-induced 
hypertension
blood pressure, 
serum albumin, 
serum urea 
nitrogen, serum 
creatinine, kidney 
weight, urinary 
sodium
Wang et al., 
2006 
Hydrodynamic
/Viral 
pU6 vector Luciferase n.a. n.a. uptake 
Kobayashi 
et al., 2004 
Lipid 
Lipoproteins, 
albumin 
apoB1, apoM n.a. n.a. 
Uptake, binding 
affinity to 
lipoproteins and 
albumin
Wolfrum et 
al., 2007 
Lipid 
Lipofectamin
e2000 
p53 
Acute 
renal 
injury 
Ischemic and 
cisplatin-
induced acute 
injury 
Histological 
scoring, apoptosis 
Molitoris et 
al., 2009 
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Delivery 
method 
Carrier Target RNA Disease Model Functional assays Author 
Lipid 
DOTAP/DO
PE, 
DOTAP/DO
PE/ 
DOPE-
PEG2000 
COX-2 
Breast 
adeno-
carcinoma
MDA-MB-231 
breast cancer 
xenograft-
bearing mouse
Cell viability, 
uptake 
Mikhaylov
a et al., 
2009 
Lipid Cholesterol
12/15-
lipoxygenase
Diabetic 
nephro-
pathy 
Streptozotocin
-induced 
diabetes 
Albuminuria, 
urinary creatinine, 
histology, type I 
and IV collagen, 
TGF-ǃ, fibronectin, 
plasminogen 
activator inhibitor 1 
Yuan et al., 
2008 
Lipid 
Lipofectamine
2000 
Mitochondrial 
membrane 44 
(TIM44) 
Diabetic 
nephro-
pathy 
Streptozotocin
-induced 
diabetes 
Cell proliferation 
and apoptosis, 
histology,  ROS, 
mitochondrial 
import of Mn-SOD 
and glutathione 
peroxidase, cellular 
membrane 
polarization 
Y. Zhang et 
al., 2006 
Hydrodynamic
/ Lipid 
Proteolipo-
some 
RLIP76 
Renal 
carcinoma
Caki-2 kidney 
cancer 
xenograft-
bearing mouse
uptake 
Singhal et 
al., 2009 
Polymer 
PEGylated 
PEI 
Luciferase 
pGL3 
n.a. n.a. 
Uptake, 
biodistribution, 
erythrocyte 
aggregation
Malek et 
al., 2009 
Polymer 
PEGylated 
poly-L-lysine
MAPK1 
Lupus 
glomerulo-
nephritis
Glomerulo-
nephritis 
Proteinuria, 
glomerulosclerosis, 
TGF- ǃ, , 
fibronectin, 
plasminogen 
activator inhibitor 1 
Shimizu et 
al., 2010 
Polymer/Nano
particle 
Hyaluronic 
acid/ 
Quantum 
dot/ PEI 
VEGF 
Kidney 
cancer/
melanoma
B16F1 
melanoma 
tumor-bearing 
mouse 
Biodistribution, 
citotoxicity, tumor 
volume, 
endocytosis 
Jiang et al., 
2008 
Polymer/Nano
particle 
PEGylated 
polycapro-
lactone 
nanofiber 
GAPDH n.a. n.a. 
cell viability, 
uptake 
Cao et al, 
2010 
Aptamer 
Spiegelmer 
mNOX-E36
CC chemokine 
ligand 2 
Glomerulo
sclerosis 
Uninephrecto-
mized mouse
urinary albumin, 
urinary creatinine, 
histopathology, 
glomerular 
filtration rate, 
macrophage count, 
serum Ccl2, Mac-
2+, Ki-67+
Ninichuk et 
al., 2008 
www.intechopen.com
 
Delivery Methods to Target RNAs in the Kidney 
 
275 
Delivery 
method 
Carrier Target RNA Disease Model Functional assays Author 
Aptamer 
Aptamer 
NOX-F37 
vasopressin 
(AVP) 
Congestive
heart 
failure 
n.a. 
Binding affinity to 
D-AVP, Inhibition 
of AVP Signaling, 
Urine 
osmolality and 
sodium 
concentration, 
Purschke et 
al., 2006 
Aptamer 
Aptamer A1, 
A2, and A3 
glutamate 
receptor 
subunit 
1(GluR1) 
n.a. 
Human 
embryonic 
kidney 293 
binding 
Liu et al., 
2009 
Table 1. Application of RNA interference in kidney disease models. 
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